Evidence map›Paper›PMID 30541756›Full record

ArticleThe oncologist2019

Nathan D Seligson, Esko A Kautto, Edward N Passen, Colin Stets, Amanda E Toland, Sherri Z Millis, Christian F Meyer, John L Hays, James L Chen

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nathan D SeligsonDivision of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Esko A KauttoBiomedical Sciences Graduate Program, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Edward N PassenDivision of Bioinformatics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Colin StetsDivision of Bioinformatics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Amanda E TolandDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Sherri Z MillisFoundation Medicine Inc., Cambridge, Massachusetts, USA.
Christian F MeyerJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
John L HaysDivision of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
James L ChenDivision of Bioinformatics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA james.chen@osumc.edu.
The Ohio State University · USFoundation Medicine (United States)Johns Hopkins University · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSoft-tissue sarcomas (STS) describe a heterogeneous group of mesenchymal tumors with limited treatment options. Targeted therapies exist for MATERIALS AND

methodsDNA sequencing data were analyzed for HR pathway alterations for 1,236 patients with STS. DNA sequencing data from an additional 1,312 patients were used to confirm the prevalence of HR pathway alterations in LMS. Four uterine LMS (uLMS) patients with functional

resultsIn an unselected STS study population,

conclusionHR pathway alterations are rare in most STS. However, we identify uLMS to be enriched for IMPLICATIONS FOR PRACTICE: Soft-tissue sarcomas are a highly morbid, diverse set of tumors with limited treatment options. This study identifies an increased prevalence of functional

Indexed as

MutationAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinFemaleFollow-Up StudiesGene DeletionGene Expression Regulation, NeoplasticHumansLeiomyosarcomaMaleMiddle AgedAntineoplastic AgentsBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsDNA repairHomologous recombinationPoly (ADP‐ribose) polymerase inhibitorsSarcoma

Identifiers

PMID30541756
PMCPMC6656468
OpenAlexW2904093244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.